Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | FS118 |
| Synonyms | |
| Therapy Description |
FS118 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially resulting in increased anti-tumor immune response (PMID: 32299814). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| FS118 | Immune Checkpoint Inhibitor 150 LAG3 Antibody 19 PD-L1/PD-1 antibody 132 | FS118 is a bispecific antibody that targets both PD-1 (PDCD1) and LAG3, potentially resulting in increased anti-tumor immune response (PMID: 32299814). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03440437 | Phase I | FS118 | FS118 First in Human Study in Patients With Advanced Malignancies After PD-1/PD-L1 Containing Therapy | Terminated | USA | FRA | 0 |